Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
508.99
-2.75 (-0.54%)
Mar 25, 2025, 4:00 PM EST - Market closed
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,100 employees as of December 31, 2024. The number of employees increased by 700 or 12.96% compared to the previous year.
Employees
6,100
Change (1Y)
700
Growth (1Y)
12.96%
Revenue / Employee
$1,806,574
Profits / Employee
-$87,803
Market Cap
130.72B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6,100 | 700 | 12.96% |
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | 3,000 | 500 | 20.00% |
Dec 31, 2018 | 2,500 | 200 | 8.70% |
Dec 31, 2017 | 2,300 | 150 | 6.98% |
Dec 31, 2016 | 2,150 | 200 | 10.26% |
Dec 31, 2015 | 1,950 | 120 | 6.56% |
Dec 31, 2014 | 1,830 | 30 | 1.67% |
Dec 31, 2013 | 1,800 | -400 | -18.18% |
Dec 31, 2012 | 2,200 | 200 | 10.00% |
Dec 31, 2011 | 2,000 | 309 | 18.27% |
Dec 31, 2010 | 1,691 | 259 | 18.09% |
Dec 31, 2009 | 1,432 | 99 | 7.43% |
Dec 31, 2008 | 1,333 | 183 | 15.91% |
Dec 31, 2007 | 1,150 | 188 | 19.54% |
Dec 31, 2006 | 962 | 149 | 18.33% |
Dec 31, 2005 | 813 | 77 | 10.46% |
Dec 31, 2004 | 736 | 12 | 1.66% |
Dec 31, 2003 | 724 | -256 | -26.12% |
Dec 31, 2002 | 980 | -20 | -2.00% |
Dec 31, 2001 | 1,000 | 545 | 119.78% |
Dec 31, 2000 | 455 | 102 | 28.90% |
Dec 31, 1999 | 353 | 13 | 3.82% |
Dec 31, 1998 | 340 | 120 | 54.55% |
Dec 31, 1997 | 220 | 42 | 23.60% |
Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VRTX News
- 14 days ago - Stocks beating the stock market's recent Trump slump have this in common - Market Watch
- 14 days ago - Top 3 Health Care Stocks That May Keep You Up At Night In Q1 - Benzinga
- 15 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 18 days ago - Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
- 19 days ago - Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating - Seeking Alpha
- 22 days ago - Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript) - Seeking Alpha
- 25 days ago - Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations - Business Wire
- 5 weeks ago - Vertex to Participate in Upcoming March Investor Conferences - Business Wire